87 related articles for article (PubMed ID: 18513951)
1. Effects of alpha/beta-androstenediol immune regulating hormones on bone remodeling and apoptosis in osteoblasts.
Urban NH; Chamberlin B; Ramage S; Roberts Z; Loria RM; Beckman MJ
J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):223-9. PubMed ID: 18513951
[TBL] [Abstract][Full Text] [Related]
2. Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand.
Wang QP; Yang L; Li XP; Xie H; Liao EY; Wang M; Luo XH
Bone; 2012 Sep; 51(3):515-23. PubMed ID: 22634178
[TBL] [Abstract][Full Text] [Related]
3. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
5. Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.
Jurado S; Garcia-Giralt N; Díez-Pérez A; Esbrit P; Yoskovitz G; Agueda L; Urreizti R; Pérez-Edo L; Saló G; Mellibovsky L; Balcells S; Grinberg D; Nogués X
J Cell Biochem; 2010 May; 110(2):304-10. PubMed ID: 20225238
[TBL] [Abstract][Full Text] [Related]
6. Expression of RANKL/OPG during bone remodeling in vivo.
Tanaka H; Mine T; Ogasa H; Taguchi T; Liang CT
Biochem Biophys Res Commun; 2011 Aug; 411(4):690-4. PubMed ID: 21771583
[TBL] [Abstract][Full Text] [Related]
7. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Giner M; Rios MJ; Montoya MJ; Vázquez MA; Miranda C; Pérez-Cano R
Eur J Pharmacol; 2011 Jan; 650(2-3):682-7. PubMed ID: 21050847
[TBL] [Abstract][Full Text] [Related]
8. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
[TBL] [Abstract][Full Text] [Related]
9. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
Tat SK; Pelletier JP; Mineau F; Caron J; Martel-Pelletier J
Bone; 2011 Sep; 49(3):559-67. PubMed ID: 21700005
[TBL] [Abstract][Full Text] [Related]
10. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast.
Baldock PA; Thomas GP; Hodge JM; Baker SU; Dressel U; O'Loughlin PD; Nicholson GC; Briffa KH; Eisman JA; Gardiner EM
J Bone Miner Res; 2006 Oct; 21(10):1618-26. PubMed ID: 16995817
[TBL] [Abstract][Full Text] [Related]
12. RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis.
Giner M; Rios MA; Montoya MA; Vázquez MA; Naji L; Pérez-Cano R
J Steroid Biochem Mol Biol; 2009 Jan; 113(1-2):46-51. PubMed ID: 19073256
[TBL] [Abstract][Full Text] [Related]
13. 99Tc-MDP-induced human osteoblast proliferation, differentiation and expression of osteoprotegerin.
Chen J; Lan Y; He Y; He C; Xu F; Zhang Y; Zhao Y; Liu Y
Mol Med Rep; 2017 Aug; 16(2):1801-1809. PubMed ID: 28656306
[TBL] [Abstract][Full Text] [Related]
14. RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects.
Corrado A; Neve A; Macchiarola A; Gaudio A; Marucci A; Cantatore FP
J Rheumatol; 2013 May; 40(5):684-94. PubMed ID: 23457386
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
16. Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats.
Charoenphandhu N; Teerapornpuntakit J; Methawasin M; Wongdee K; Thongchote K; Krishnamra N
Can J Physiol Pharmacol; 2008 May; 86(5):240-8. PubMed ID: 18432284
[TBL] [Abstract][Full Text] [Related]
17. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
Persson E; Lerner UH
J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
[TBL] [Abstract][Full Text] [Related]
18. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
[TBL] [Abstract][Full Text] [Related]
19. In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol.
Padgett DA; Loria RM
J Immunol; 1994 Aug; 153(4):1544-52. PubMed ID: 8046232
[TBL] [Abstract][Full Text] [Related]
20. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]